Artelo Biosciences (ARTL) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
14 May, 2026Management team and governance
Principal executive officers include the President/CEO, CFO, and several directors, all of whom have signed the registration statement as of May 14, 2026.
The company is incorporated in Nevada and operates from Solana Beach, CA.
Indemnification agreements are in place for directors and officers, providing maximum protection allowed by Nevada law, and the company maintains insurance for these individuals.
Offering details and pricing
The registration statement is filed on Form S-3, allowing for the offer and sale of securities from time to time after effectiveness.
The offering may include various types of securities, including debt securities, as detailed in the filed Indenture.
Estimated SEC registration fee is $788.05, with additional fees for accounting, legal, and other services to be determined based on the size and type of offering.
Unsold securities from a previous registration statement will have their registration fees carried forward.
Underwriters and syndicate
The form of underwriting agreement is listed as an exhibit, to be filed by amendment or incorporated by reference.
Latest events from Artelo Biosciences
- Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.ARTL
H.C. Wainwright 26th Annual Global Investment Conference 202430 Jun 2026 - Shareholders will vote on director elections, a large share increase, and a major equity issuance.ARTL
Proxy filing22 Jun 2026 - Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.ARTL
Corporate presentation5 Jun 2026 - Vote on director elections and a major increase in authorized shares at the 2026 annual meeting.ARTL
Proxy filing5 Jun 2026 - Shareholders will vote on director elections and a major increase in authorized common stock.ARTL
Proxy filing5 Jun 2026 - Lead drug candidates show strong progress in major markets with robust safety and efficacy data.ARTL
Corporate presentation26 May 2026 - Shareholders will vote on director elections and a major increase in authorized common stock.ARTL
Proxy filing26 May 2026 - Q1 2026 net loss reached $3.0M; cash at $10.3M after $10M financing, but going concern risk remains.ARTL
Q1 202615 May 2026 - Advancing novel lipid signaling drugs with strong clinical data and large market potential.ARTL
Corporate presentation14 May 2026